take share name
thesi updat undeni clear us post
take share broad base fei pthn
may turn epic transact life
strength much widespread us quit
impress also made nois omx
would note guidanc cadenc predict mis-
model defer revenu headwind pthn revers
thu would take much issu margin oi
growth doubl digit omx assumpt materi
furthermor strike us post much balanc sheet
capac beyond flow gener
strong ebitda growth superior sizeabl
deal tabl nice potenti upsid
surpris go forward also think defens natur
type market would note think
compani deliv environ wors next
year even fear recess argu busi
defens consum pharma exposur last
cycl held serv ep roll
dont see ignor own despit valuat
cheap rel market superior asset
deserv frankli remain buyer term tweak
ep better core lower fx
conserv view capit deploy push larg deal
conservat pt move impli teen
end market grew msd biopharma led high-
rais revenu ep guidanc due strong perform
geograph region grew hsd apac lead
pleas see analyst certif import disclosur page report evercor isi affili seek busi
compani cover research report investor awar firm may conflict interest could affect object
report investor consid report singl factor make invest decis
mix dynam pressur margin strength lp specialti
dx howev tighter rang org growth expect
china tariff growth impact updat mm howev
expect off-set full w/ price suppli chain
rais vs prior reflect mm
org growth increas mm org growth
increas maintain maintain
fx tw
rais ep vs prior
tax reduct less favor addtl
rais incom expens mm
slight improv due non-operating fx benefit
realiz
prior due higher interest incom activ
manag debt profil
maintain mm share buyback
alreadi execut
slight chang composit tariff growth impact
howev execut offset price suppli
chain tariff net impact year
deliv adjust ep stronger oper
perform line fx tw lower interest cost
tax off-set increas reinvest biz
three busi dd growth
grow market take share well
gener better theyv seen year
grow market take share
book grew faster rev posit book
bill
w/ regard pull forward see
anyth ordinari w/ buy
chines government need thermo good
also make adjust price suppli
chain off-set tariff impact
biopharma high-teen continu see strength across
busi signific share gain
grow market take share
 msd continu posit fund dynam
nih environ good posit outlook
ww demand
om yoy impact acquisit fx
contribut ppi biz system larg off-set biz
gm yoy strong product off-set
dilut impact acq unfavor biz mix strateg
adj tax rate bp due us tax reform
 pipelin remain busi short-term impact macro
dont signific effect environ
track deploy bn fy
return mm capit mm buyback
valuat methodolog base mix discount cash flow analysi rel valuat multipl
risk valuat includ regulatori risk overal market risk well unforeseen event relat individu cover
compani broader sector includ new competit product technolog
laboratori corp america
articl articl
time dissemin octob
analyst luke sergott ross muken primarili respons prepar research report attest follow view
opinion render research report reflect person view subject compani issuer part
research analyst compens directli relat specif recommend view research report
